Survivin Loss in Thymocytes Triggers p53-mediated Growth Arrest and p53-independent Cell Death

Hitoshi Okada,1,2 Chris Bakal,2,4 Arda Shahinian,1,2 Andrew Elia,1,2 Andrew Wakeham,1,2 Woong-Kyung Suh,1,2 Gordon S. Duncan,1,2 Maria Ciofani,4,5 Robert Rottapel,2,4 Juan Carlos Zúñiga-Pflücker,4,5 and Tak W. Mak1,2,3,4

1Advanced Medical Discovery Institute, 2Ontario Cancer Institute, 3Department of Medical Biophysics, and 4Department of Immunology, University of Toronto, Toronto, Ontario M5G 2C1, Canada
5Sunnybrook and Women’s College Health Sciences Center, Toronto, Ontario M4N 3M5, Canada

Abstract

Because survivin-null embryos die at an early embryonic stage, the role of survivin in thymocyte development is unknown. We have investigated the role by deleting the survivin gene only in the T lineage and show here that loss of survivin blocks the transition from CD4−CD8− double negative (DN) thymocytes to CD4+CD8+ double positive cells. Although the pre–T cell receptor signaling pathway is intact in survivin-deficient thymocytes, the cells cannot respond to its signals. In response to proliferative stimuli, cycling survivin-deficient DN cells exhibit cell cycle arrest, a spindle formation defect, and increased cell death. Strikingly, loss of survivin activates the tumor suppressor p53. However, the developmental defects caused by survivin deficiency cannot be rescued by p53 inactivation or introduction of Bcl-2. These lines of evidence indicate that developing thymocytes depend on the cytoprotective function of survivin and that this function is tightly coupled to cell proliferation but independent of p53 and Bcl-2. Thus, survivin plays a critical role in early thymocyte development.

Key words: pre–T cell • cell death • development • thymus • mitosis

Introduction

T lymphocyte development in thymus is a complex process involving distinct stages of proliferation and cell death. These stages are defined by the expression of specific cell surface markers, commencing with CD4−CD8− double negative (DN) cells, which proliferate and differentiate into CD4+CD8− double negative (DN) cells, which proliferate and differentiate into CD4+CD8+ double positive (DP) cells. DP thymocytes then undergo a culling process involving induced cell death that results in populations of terminally differentiated CD4+ or CD8+ single positive (SP) cells. The SP thymocytes are released from the thymus to become mature peripheral T cells. DN thymocytes are not only classified by their lack of expression of CD4 and CD8, but also by their differential expression of CD44 (Pgp-1) and CD25 (IL-2 receptor α chain): DN1 (CD44+CD25−), DN2 (CD44+CD25−), DN3 (CD44+CD25+), and DN4 (CD44+CD25−; reference 1). The DN3 stage is then subdivided according to CD44/CD25 expression or cell size: DN3E (CD44−CD25−low) and DN3L (CD44−CD25−high). Productive rearrangement of the TCRβ locus takes place during the DN3 to DN4 transition and leads to pre-TCR expression. Only cells expressing a functional pre-TCR undergo exponential expansion, a process referred to as β-selection (2–4).

Survival signals in early thymocyte progenitors are mediated mainly by IL-7 and stem cell factor. IL-7 prevents CD25+ pre–T cells from undergoing cell death by up-regulating expression of the antiapoptotic gene Bcl-2 (5–7). Once a functional pre-TCR is formed at the DN3 stage, however, the pre-TCR takes over and provides survival signals allowing pre–T cells to advance to the DP stage. It remains unclear precisely which downstream signaling molecules are mobilized by the pre-TCR to control survival. Bcl-2 does not...
appear to play as important a role as in the early progenitor stage because Bcl-2 expression decreases through the DN3L to DN4 transition (8) and is rarely detected in DN4 cells (9, 10). Several lines of evidence also suggest that a checkpoint dependent on the tumor suppressor p53 exists in pre-T cells to inhibit premature differentiation of thymocytes before expression of the pre–TCR complex. Induction of p53 deficiency in CD3γ-deficient (11), RAG-deficient (12), or SCID mice (13–15), all of which lack a functional pre–TCR, rescues the block in DN thymocyte development. Therefore, it has been proposed that p53 may act as a sensor for β-selection. Only thymocytes that express a functional pre–TCR succeed in inactivating the p53-induced cell death pathway and go on to the DP stage.

The cycling and division of almost all cell types are tightly regulated by the controlled activation and inactivation of precise checkpoint mechanisms. Many types of cellular stresses trigger p53, which in turn activates both the G1/S and G2/M cell cycle checkpoints (16, 17). However, damage to the mitotic spindle triggers the p53-independent spindle checkpoint, halting the cell cycle at the metaphase–anaphase transition (18). Cells with wild-type p53 and its target gene p21 then undergo a form of G1 arrest characterized by resistance to antimicrotubule agents (19, 20). In contrast, p53-deficient cells do not arrest in G1 and instead endoreplicate their DNA, resulting in cell death due to aberrant mitosis (21, 22).

Survivin is a member of the inhibitor of apoptosis family (23) but its direct role in apoptosis is still controversial. For example, survivin displays no ability to suppress caspase-3 activity in vitro and does not bind procaspase-9 (24). Survivin is not highly expressed in most adult tissues, but this protein becomes prominent in fast-growing cells such as transformed cell lines and human cancers (23). Accordingly, survivin expression is regulated in a cell cycle–dependent fashion (25, 26). Immunohistochemical analysis has shown that survivin associates with mitotic spindle microtubules, centromeres, and intracellular mid-bodies (27, 28). Recent studies have also shown that survivin is a chromosomal passenger protein that regulates chromosome segregation by interacting with other passenger proteins, such as inner centromere protein and Aurora-B kinase (29). Inactivation of mammalian survivin or its orthologues in lower organisms results in cytokinesis abnormalities (30–32), particularly spindle defects (33).

Because survivin-null embryos die at an early embryonic stage (28, 34), conventional knockout mice cannot provide any information on the role of survivin in organogenesis. To address whether survivin requirement is tissue specific, we have generated conditional knockout mice in which the survivin gene is deleted only in the T lineage. This is also an ideal tool to investigate whether survivin directly regulates apoptosis. We found that these animals had few peripheral T cells or SP or DP thymocytes because thymocyte development was impaired at the DN3 to DN4 transition. Mislocalization of proteins crucial for spindle formation was evident in mutant thymocytes. Ex vivo analysis revealed that survivin-deficient thymocytes at the DN3 to DN4 transition underwent cell cycle arrest and cell death. Although loss of survivin induced p53 and p21, neither p53 loss nor introduction of a Bcl-2 transgene could restore the development of survivin-deficient DN3 thymocytes. These results demonstrate that survivin plays an essential role in early thymocyte development and that the cytoprotective function of survivin cannot be replaced by overexpression of Bcl-2 or loss of p53.

**Materials and Methods**

**Generation of Lck-Cre; survivinfl/fl Mice.** Three independent overlapping genomic survivin clones were isolated from a 129/Sv library and used to construct a targeting vector (see Fig. 1) that was electroporated into E14K embryonic stem (ES) cells (129/Ola). Homologous recombinants were used to generate chimeric mice and survivinfl/fl mice after the removal of the neo cassette by transient expression of Flpe recombinase in vitro (35). Germ-line transmission was confirmed by Southern blot analysis of tail DNA as previously described (36). The primer sequences for genomic DNA PCR are available upon request.

**Histological Analysis.** Thymi were fixed overnight at 4°C in freshly prepared 4% paraformaldehyde/PBS and processed for histology. Serial sections were stained with hematoxylin and eosin using standard protocols.

**Flow Cytometric Analysis and Cell Sorting.** Anti-CD4, CD8, CD25, CD44, B220, CD11c, NK1.1, TCRβ, TER-119, Mac-1, Gr-1, and heat stable antigen (HSA) mAbs were from BD Biosciences. These mAbs were directly coupled to FITC, PE, allophycocyanin, or biotin. Surface marker expression by thymocytes and peripheral T cells was analyzed using a flow cytometer (FACSCalibur™; Becton Dickinson) and CELLQuest™ software according to standard protocols. Intracellular staining was performed using the Cell Fixation/Permeabilization Kit (BD Biosciences). Cell sorting was performed by FACS Vantage™ (Becton Dickinson). For DN thymocytes, CD4+ CD8+ cells and B220+ cells were depleted using a mixture of CD4/CD8/B220 magnetic beads (Dynal). After two rounds of depletion, the cells were preincubated with Fc-Block (BD Biosciences) and stained with mAbs. DN3E cells were taken as HSA+ CD44+, whereas DN4 cells were Lin− CD25− CD44+. DN3L to DN4 transition underwent cell cycle arrest and cell death. Although loss of survivin induced p53 and p21, neither p53 loss nor introduction of a Bcl-2 transgene could restore the development of survivin-deficient DN3 thymocytes. These results demonstrate that survivin plays an essential role in early thymocyte development and that the cytoprotective function of survivin cannot be replaced by overexpression of Bcl-2 or loss of p53.
RT-PCR Analysis. Total RNA was extracted from thymocytes using TRIzol (Life Technologies). cDNA was generated with the SuperScript First-Strand Synthesis System (Invitrogen). The primer sequences for RT-PCR are available upon request.

Immunofluorescence Microscopy. Cells were fixed in cold methanol or in freshly prepared 4% paraformaldehyde/PBS and permeabilized in 0.2% Triton X-100/PBS. Alternatively, cells were pre-extracted with 0.2% Triton X-100 in PHEM buffer (80 mM Pipes, 20 mM Hepes, 1 mM EGTA, and 2 mM MgCl₂, pH 6.8). Samples were simultaneously fixed and extracted with 0.5% Triton X-100, 3.7% formalin, and 0.25% glutaraldehyde in PHEM buffer. Slides were blocked in 0.5% BSA/0.02% glycine/PBS and labeled with primary and secondary antibodies. Hoechst 33258 (Molecular Probes) was used to stain DNA. Images were obtained using an Olympus 1X-70 inverted microscope and Deltavision Deconvolution Microscopy software (Applied Precision). The following primary antibodies were used: mouse anti-bovine α-tubulin (Molecular Probes), mouse anti-IAP/Aurora-A kinase and mouse anti–AIM/Aurora-B kinase (Transduction), rabbit anti–pericentrin (Covance), and mouse anti–phospho-histone H3 (Upstate Biotechnology). The following secondary antibodies were used: Oregon green 488 goat anti-rabbit IgG, Oregon green 488 goat anti–mouse IgG, Alexa Fluor 594 goat anti–mouse IgG, and Texas red goat anti–rabbit IgG (Molecular Probes).

Apoptosis Assays. Evaluation of thymocyte apoptosis in vitro was performed using the Apoptosis Detection Kit (R&D Systems) as previously described (36).

Results

Generation of Thymocyte-specific Survivin-deficient Mice. We constructed a survivin-targeting vector in which the neo cassette was flanked by FRT sequences and survivin exon 2 was flanked by loxP sequences (Fig. 1 A). Therefore, Cre-mediated removal of exon 2 resulted in an early frameshift and translation termination. The conditional targeting vector was used to generate two independent ES cell lines carrying a floxed survivin allele (survivin<sup>flox/flox</sup> mice). Survivin<sup>flox/flox</sup> mice were born at the expected Mendelian ratio and displayed no abnormalities (not depicted), indicating that genetic manipulation of the survivin gene did not interfere with survivin function. Survivin<sup>flox/flox</sup> mice were crossed with Lck-Cre transgenic mice (41) to generate thymocyte-specific survivin-deficient mice (Lck-survivin<sup>flox/flox</sup>). The lack of survivin protein in DN thymocytes was demonstrated by Western blot analysis of survivin protein levels (Fig. 1 C). In addition, genomic DNA prepared from sorted DN cells was analyzed by PCR for the detection of the floxed or deleted (Δflox) survivin
allele. The floxed allele was deleted in the majority of DN2 and DN3E cells and almost all DN3L and DN4 cells in the mutants (Fig. 1 D).

Defects in Thymocyte Development in Lck-survivinfloxflox Mice. We first compared the level of survivin expression in DN subpopulations in mutant and control mice. RT-PCR analysis showed that survivin mRNA was maximally expressed at the DN3L stage in control cells (Fig. 2 A). Flow cytometric analysis demonstrated that compared with Lck-survivin+/+ cells, intracellular survivin expression was decreased in Lck-survivinfloxflox cells starting at the DN2 stage (Fig. 2 B). This time frame is consistent with Lck proximal promoter activity (42).

Next, we determined numbers of peripheral T cells and thymocyte subpopulation proportions in Lck-survivinfloxflox and Lck-survivinflox/flox mice at 6–8 wk of age. Flow cytometric analysis revealed that the number of peripheral TCRαβ+ cells was dramatically reduced in Lck-survivinfloxflox mice (Fig. 2 C, top). The average number of thymocytes recovered from Lck-survivinfloxflox mice was 2.41 ± 0.5 × 10⁶ (n = 6), ~2.0% of the number of thymocytes in Lck-survivin+/+ mice (1.22 ± 0.6 × 10⁶; n = 6). Moreover, ~95% of Lck-survivinfloxflox thymocytes were DN cells (Fig. 2 C, middle), suggesting that the loss of survivin affected either the DN to DP transition or the production of DN cells. To distinguish between these possibilities, we stained DN cells from control and mutant mice with the early developmental markers CD25 and CD44 (Fig. 2 C, bottom). DN3 (CD25−CD44+) cells represented ~80% of Lck-survivinfloxflox DN cells compared with <50% of DN cells in Lck-survivin+/+ or Lck-survivinfloxflox mice. DN4 (CD25−CD44−) cells were reduced to 4% in Lck-survivinfloxflox mice compared with 30 and 34% in Lck-survivin+/+ and Lck-survivinfloxflox mice, respectively.

Histological findings confirmed the block in the DN3 to DN4 transition in the absence of survivin. Thymi in Lck-survivinfloxflox mice...
survivin\textsuperscript{floxFloX} mice had a typical structure and contained a cortex (Fig. 2 D, left, dark purple area) with immature T cells and a medulla (Fig. 2 D, left, light purple area) with smaller DP cells. In contrast, thymi of Lck-survivin\textsuperscript{flox/flox} mice were much smaller and lacked cortex-medulla compartmentalization (Fig. 2 D, right). The vast majority of thymic cells in the mutants were large and stained light purple, which are characteristics of immature thymocytes. These results indicate that in the absence of survivin, DN thymocytes fail to expand and progress to the DP stage.

**Normal TCRβ Gene Rearrangement and In Vitro Pre-TCR Signaling in Survivin\textsuperscript{flox/flox} DN Thymocytes.** The accumulation of DN3 thymocytes in Lck-survivin\textsuperscript{flox/flox} mice was strikingly similar to that in RAG-1 (43), RAG-2 (44), TCRβ (45), and Lck (46) knockout mice. Therefore, we analyzed the rearrangement of the TCRβ locus, a requirement for the DN3 to DN4 transition. Analysis of DN thymocyte DNA by PCR and Southern blotting showed that somatic recombination of DB2-Jβ2 gene segments was not altered in survivin-deficient thymocytes (Fig. 3 A). Furthermore, flow cytometry revealed no differences in intracellular TCRβ protein between DN3E and DN3L thymocytes from Lck-survivin\textsuperscript{flox/flox} and Lck-survivin\textsuperscript{flox/flox} mice were surface stained with anti-CD25, anti-CD44, and anti-Lin followed by intracellular staining with TCRβ and flow cytometric analysis. (C) Normal MAPK activation. Lck-survivin\textsuperscript{flox/flox} and Lck-survivin\textsuperscript{floxFloX} DN thymocytes were treated with anti-CD3e-biotin followed by cross-linking with avidin for the indicated times. Protein lysates were subjected to Western blot analysis using anti–phospho-ERK Abs. (D) Impaired in vivo response of survivin-deficient thymocytes to anti-CD3e. RAG-2\textsuperscript{-/-}DN3 cells, Lck-survivin\textsuperscript{flox/flox}DN3 cells failed to advance to DN4. Data shown are representative of three independent experiments.
cells in RAG-2−/− mice in the absence of pre-TCR signaling (48). Therefore, we treated Lck-survivinflox/flox and RAG-2−/− mice with anti-CD3ε Ab and isolated DN thymocytes 72 h after injection. Although anti-CD3ε Ab induced the differentiation and proliferation of DN3 cells in RAG-2−/− mice, it failed to do so in Lck-survivinflox/flox mice (Fig. 3 D). These results indicate that the loss of survivin does not affect TCRβ rearrangement, intracellular TCRβ expression, or the pre-TCR signaling pathway itself. However, the DN3 to DN4 transition cannot be rescued by a surrogate pre-TCR signal in the absence of survivin, suggesting that survivin plays a critical role in highly proliferative cells.

Impaired Proliferation and Increased Cell Death of Lck-survivinflox/flox DN Thymocytes. Because the pre-TCR signaling required for DN cell proliferation was normal in Lck-survivinflox/flox thymocytes, we investigated whether the loss of DN4 cells in the mutant mice was due to impaired proliferation or increased apoptosis or both. Annexin V staining for cell viability in vivo showed that 37% of DN3L and 32% of DN4 cells were annexin+ in Lck-survivinflox/flox mice (Fig. 4 A). In contrast, only 5–7% cells were annexin+ in control mice, indicating that loss of survivin induces apoptosis of DN3L and DN4 thymocytes.

To test whether loss of survivin impaired cellular responses to external apoptotic stimuli, we subjected purified DN cells from Lck-survivinflox/flox and RAG-2−/− mice to treatment with etoposide (Etp), dexamethasone (Dex), γ-irradiation (IR), and staurosporine (STS). About 90% of thymocytes in both mutant strains are DN3E cells. When apoptosis was evaluated at 16 h after treatment, no significant differences in the numbers of apoptotic cells were observed under any conditions tested (Fig. 4 B). These results indicate that survivin is not essential in DN3E cells for the execution of apoptosis in response to various external stimuli in vitro. However, a failure in survivin function triggers the death of proliferating cells in vivo. To examine the effect of survivin loss on the cell cycle, DN thymocytes were pulse labeled in vivo with BrdU and stained with anti-BrdU Ab and 7AAD in vitro (Fig. 4 C). The cell cycle profile of DN3E cells was comparable in Lck-survivinflox/flox and Lck-survivinflox/flox mice (Lck-survivinflox/flox: G1, 77.1%; S, 21.0%; G2/M, 0.3% vs. Lck-survivinflox/flox: G1, 77.6%; S, 20.2%; G2/M, 0.6%). However,
in Lck-survivinflox/flox DN3L cells, the G1 population was increased to 33.3% (Lck-survivin\textsuperscript{+/+}: 14.8%) and the S population was decreased to 63% (Lck-survivin\textsuperscript{+/+}: 80%). In Lck-survivinflox/flox DN4 cells, the G1 population was increased still further to 67.4% (Lck-survivin\textsuperscript{+/+}: 43.7%), whereas the S population dropped to 19.6% (Lck-survivin\textsuperscript{+/+}: 53.0%). In addition, sub-G1 cells represented 3.0% of DN4 thymocytes in Lck-survivin flox/flox mice but only 0.1% of control DN4 cells. Thus, survivin is required for the proliferation and survival of DN3L and DN4 thymocytes, and a lack of survivin leads to cell cycle arrest and cell death at these stages.

**Defects in Cytokinesis in Lck-survivin\textsuperscript{floxFlox} DN Thymocytes.** Embryos of mice with a null mutation of the survivin gene show a cytokinesis defect and die early during embryogenesis (28, 34, and unpublished data). Overexpression of dominant negative survivin or antisense inactivation of survivin also lead to cytokinetic defects (25, 27) and anti-survivin Ab injection results in spindle defects (49). We examined spindle formation in DN3L and DN4 cells from Lck-survivin\textsuperscript{floxFlox} and Lck-survivin\textsuperscript{+/+} mice by staining thymocytes with α-tubulin. Lck-survivin\textsuperscript{+/+} (and Lck-survivin\textsuperscript{floxFlox}) cells had well-organized and symmetrical spindles (Fig. 5 A, a), whereas Lck-survivin\textsuperscript{floxFlox} cells showed shorter and thicker spindles (Fig. 5 A, b). The number of spindle fibers was reduced in many cases, suggesting a defect in the assembly of spindle microtubules. Significantly, we found that microtubule assembly defects were enhanced in mitotic mutant cells compared with interphase mutant cells (Fig. 5 B). Thus, the organization and assembly of mitotic spindles is severely impaired in the absence of survivin.

Because the intracellular localization of lpl1/Aurora kinase in *Caenorhabditis elegans* is affected by the loss of the survivin orthologue bir-1 (32), we examined the localization of murine Aurora-B kinase (Aurora-B) at each mitotic stage in DN cells of control and survivin-deficient mice. In wild-type cells, Aurora-B localized at the centromeres until metaphase (Fig. 5 C, b), transferred to the central spindle during anaphase (Fig. 5 C, c), and finally accumulated at the spindle midbody during telophase and cytokinesis (Fig. 5 C, d). However, in survivin-deficient cells, Aurora-B could not localize at either the midzone or midbody at either anaphase or telophase (Fig. 5 C, e–h). Indeed, no typical telophase cells could be found among survivin-deficient DN thymocytes.

**p53 Induction in Lck-survivin\textsuperscript{floxFlox} DN Thymocytes.** Increased cell death and cell cycle arrest are hallmarks of p53
function. To test whether loss of survivin induced p53, we investigated the status of p53 protein in Lck-survivin flox/flox DN cells. We found that p53 protein expression was indeed induced in Lck-survivin flox/flox DN cells but not in Lck-survivin flox/+ DN cells (Fig. 6 A, top). Flow cytometric analysis of intracellular p53 protein confirmed that p53 was expressed in survivin-deficient DN2 to DN4 cells (Fig. 6 B). In addition, RT-PCR analysis showed that expression of the p53 target gene p21 was induced in Lck-survivin flox/flox cells (Fig. 6 A, bottom). These results suggested that p53 might be responsible for the increased apoptosis and arrest observed in Lck-survivin flox/flox mice.

Gain of Bcl-2 or Loss of p53 Expression Does Not Rescue DN Thymocyte Developmental Defects Induced by Survivin Loss. We determined whether Bcl-2 could rescue survivin deficiency by crossing Lck-survivin flox/flox mice to Eµ-Bcl-2 transgenic mice to generate Lck-survivin flox/flox;Bcl-2 animals. The total number of thymocytes in Lck-survivin flox/flox;Bcl-2 mice (2.2 ± 0.7 × 10^6; n = 4) was comparable to that in Lck-survivin flox/flox mice (2.4 ± 0.5 × 10^6; n = 4; Fig. 7 A). The number of DN cells was also unaltered in the presence of the Bcl-2 transgene (Lck-survivin flox/flox vs. Lck-survivin flox/flox;Bcl-2: 2.3 ± 0.5 × 10^6 vs. 2.1 ± 0.6 × 10^6; n = 4), suggesting that Bcl-2 overexpression cannot overcome cell death induced by an absence of survivin.

To test whether survivin deficiency had a direct impact on p53-mediated apoptosis, we generated compound conditional survivin mutants by crossing Lck-survivin flox/flox mice to p53−/− mice to generate Lck-survivin flox/flox;p53−/− animals. In mice lacking both survivin and p53, the total number of thymocytes was decreased (0.33 ± 0.10 × 10^6; n = 3) compared with Lck-survivin flox/flox;p53−/− controls (1.23 ± 0.12 × 10^6; n = 3). The percentage of DN thymocytes in the double mutants was decreased by 10% at most (n = 3), whereas the percentages of DP and SP thymocytes were slightly (not significantly) increased (Fig. 7 B), indicating that loss of p53 cannot restore DN thymocyte development in the absence of survivin.

Loss of p53 or p21 Expression Releases Cell Cycle Arrest but Accelerates Apoptosis Induced by Survivin Loss. Next, we examined cell cycle status and apoptosis in survivin-deficient thymocytes also lacking either p53 or p21. In both cases, the G1 subpopulation of DN3L thymocytes was restored to the control level (Lck-survivin flox/flox vs. Lck-survivin flox/flox vs. Lck-survivin flox/flox;p53−/− vs. Lck-survivin flox/flox;p21−/−: 35.3 vs. 51.1 vs. 35.6 vs. 37.0%; Fig. 7 C, middle). Thus, cell cycle arrest induced by loss of survivin is mediated by the p53 pathway and involves p21 induction. The G1 subpopulation of DN4 thymocytes was reduced by >80% regardless of genetic background, suggesting profound cell damage resulted in these cells. These results suggest that loss
of survivin, as well as triggering p53-mediated growth arrest, precipitates aberrant mitosis that inexorably causes the death of affected cells regardless of their p53 or p21 status. Indeed, annexin staining showed that the viability of DN3E and DN3L cells was significantly decreased when both survivin and either p53 or p21 were missing (Fig. 7 D). Thus, the loss of the cytoprotective function of survivin appears to trigger p53 induction and cell cycle arrest, but the death of survivin-deficient cells involves a mechanism that is independent of p53.

Discussion

In this study, we have defined the role of survivin in thymocyte development and have investigated the biochemistry underlying its effects. The conditional deletion of the survivin gene in thymocytes revealed that survivin has vital functions in both cell death and proliferation in vivo. But we could not find any evidence that survivin directly regulates apoptotic pathway.

Control of cell survival and proliferation is fundamental to normal T cell development, and signaling via the pre-TCR contributes to the regulation of both these processes during early thymocyte maturation (4, 50). Whether the pre-TCR also mediates anti-apoptosis has not been well clarified. Is survivin required for these pre-TCR–mediated signals? Our data show that the DN3 to DN4 transition is severely impaired in Lck-survivinflox/flox mice. Profound reductions in DP and SP cell numbers occur that lead to a decrease in total thymic cellularity (Fig. 2, C and D). Thus, the proliferation and survival of DN3L and DN4 cells, which are known to depend on pre-TCR signaling, are also dependent on survivin function. Once survivin is inactivated, DN3L and DN4 cells lose their ability to expand and eventually die. In our study, survivin was up-regulated during the DN3E to DN3L transition (Fig. 2, A and B), and loss of survivin led to a drastic increase in the number of cells undergoing cell cycle arrest and cell death (Fig. 4). This phenotype is reminiscent of that of mice missing any component (TCRβ, pTα, CD3 molecules) of the pre-
TCR. However, survivin-deficient DN cells retain normal expression of rearranged TCRB and pre-TCR signaling components (Fig. 3, A–C). Although anti-CD3 Ab can overcome the block in RAG-2−/− DN cells, such treatment does not restore survivin-deficient DN thymocyte development (Fig. 3 D). Thus, the initiating elements of pre-TCR signaling are intact in survivin-deficient cells but survivin is required for the actual expansion of thymocytes in response to pre-TCR signaling.

Although survivin is a member of inhibitor of apoptosis family, its direct role in apoptosis is still controversial (29, 51, 52). In our system, survivin-deficient cells exhibited normal susceptibility to various external apoptotic stimuli in vitro (Fig. 4 B). In addition, survivin deficiency in DN3E cells did not induce spontaneous apoptosis (Fig. 4 A). However, a failure in survivin function triggers cell death of highly proliferating DN cells (Fig. 4 A). Based on these findings, we conclude that survivin primarily plays a critical role in mitosis progression but does not directly regulate apoptosis. Inactivation of survivin in proliferating cells induces severe defects in chromosome segregation and cytokinesis, and subsequent cell death with the morphology representing mitotic catastrophe (not depicted). On the other hand, cofactor-dependent caspase inhibition of survivin has recently been reported (24). Further analysis of survivin’s cytoprotective functions in a tissue- or cell context–specific manner is therefore necessary.

p53 has a critical role in transducing signals from damaged DNA that control the cell cycle and apoptosis in mammalian cells (16, 17). In mutant mice with impaired pre-TCR expression, p53 deficiency can rescue the block in DN thymocyte development (11–15). This genetic evidence has suggested a model in which a p53-mediated checkpoint operates during pre-T cell development to sense and eliminate thymocytes that attempt to differentiate before the formation of a functional pre-TCR complex. In this scenario, the pre-TCR regulates the DN to DP transition by inactivating p53. However, others have suggested that the pre-TCR checkpoint may involve a p53-independent cell death pathway (11). In this study, we have shown that the death of survivin-deficient DN thymocytes involves such a pathway (Fig. 7) and we hypothesize that survivin controls critical aspects of the DN to DP transition. This hypothesis is consistent with recent reports that survivin is required for the maintenance of the spindle checkpoint. For example, in survivin-depleted cells, the spindle checkpoint molecules BubR1 and Mad2 are prematurely displaced from kinetochores and the spindle checkpoint cannot be maintained (53, 54).

We speculate that in exponentially growing DN thymocytes, survivin might be critical for maintaining the integrity of the rapidly forming spindles. Although the precise mechanism underlying the induction of p53 by spindle damage remains unknown, defects in centrosome duplication have been suggested to activate the p53 pathway (55). We found that survivin-deficient cells exhibited abnormal spindle formation (Fig. 5, A and B). Thus, the loss of survivin in the mutant cells may have activated the same p53 signaling pathway as seen in cells treated with microtubule-damaging agents (56). p53-mediated induction of p21 is required for the arrest of spindle-damaged cells at G1 (18). We also observed that p21 was highly up-regulated in survivin-deficient cells (Fig. 6 A) and that loss of p21 released the cell cycle arrest (Fig. 7 C). The p53 protein also has direct effects on other aspects of mitosis. For example, p53 controls centrosome duplication via a p21-dependent mechanism (57). p53 also binds directly to Aurora-A and suppresses Aurora-A–induced centrosome amplification (58). It is not hard to imagine that loss of survivin coupled with p53 inactivation might have cumulative devastating effects on mitosis.

Our work has generated useful genetic tools for the study of survivin functions in various tissues and pathological conditions. Further study of T cell–specific survivin-deficient mice and additional mutants should reveal much about pre-TCR signaling and the p53- and Bcl-2–independent mechanisms involved in cell death induced by loss of survivin. Research to define these pathways may shed new light on regulatory mechanisms governing cell death and proliferation, which could in turn ultimately lead to novel therapeutic targets.

We thank Jamey Marth for Lck-Cre transgenic mice; Susan Cory for Eq-Bcl-2–36 transgenic mice; Susan Demecky and A. Francis Stewart for the Fip expression vector; Dario C. Altieri for anti-survivin antibody; Scott W. Lowe, Jim Woodgett, Pamela Ohashi, San Benchimol, Danu Tang, Kathrin Zaug, and members of the Mak laboratory for helpful comments; Denis Bouchard for technical assistance; and Mary Saunders for scientific editing.

This work was supported by the Canadian Institutes of Health Research (CIHR), National Cancer Institute of Canada (NCIC), and Canadian Network for Vaccines and Immunotherapeutics (CANVAC) grants to T.W. Mak. J.C. Zúñiga-Pflücker is supported by CIHR and is the recipient of a CIHR Investigator Award. R. Rottapel is a CIHR Scientist.

Submitted: 3 December 2003 Accepted: 18 December 2003

References

1. Godfrey, D.I., J. Kennedy, T. Suda, and A. Zlotnik. 1993. A developmental pathway involving four phenotypically and functionally distinct subsets of CD3+CD4+CD8+ triple-negative adult mouse thymocytes defined by CD44 and CD25 expression. J. Immunol. 150:4244–4252.
2. Dudley, E.C., H.T. Petrie, L.M. Shah, M.J. Owen, and A.C. Hayday. 1994. T cell receptor beta chain gene rearrangement and selection during thymocyte development in adult mice. Immunity. 1:83–93.
3. Levelt, C.N., and K. Eichmann. 1995. Receptors and signals in early thymic selection. Immunology. 3:667–672.
4. von Boehmer, H., I. Aifantis, J. Feinberg, O. Lechner, C. Saint-Ruf, U. Walter, J. Buer, and O. Azogui. 1999. Pleiotropic changes controlled by the pre-T-cell receptor. Curr. Opin. Immunol. 11:135–142.
5. Akashi, K., M. Kondo, U. von Freeden-Jeffry, R. Murray, and I.L. Weissman. 1997. Bcl-2 rescues T lymphopoiesis in...
interleukin-7 receptor-deficient mice. Cell. 89:1033–1041.
6. Maraskovsky, E., L.A. O’Reilly, M. Teepe, L.M. Corcoran, J.J. Peschon, and A. Strasser. 1997. Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1−/− mice. Cell. 89:1011–1019.
7. von Freeden-Jeffry, U., N. Solvason, M. Howard, and R. Murray. 1997. The earliest T lineage-committed cells depend on IL-7 for Bcl-2 expression and normal cell cycle progression. Immunity. 7:147–154.
8. Voll, R.E., E. Jimi, R.J. Phillips, D.F. Barber, M. Rincon, A.C. Hayday, R.A. Flavell, and S. Ghosh. 2000. NF-kappa B activation by the pre-T cell receptor serves as a selective survival signal in T lymphocyte development. Immunity. 13: 677–689.
9. Sentman, C.L., J.R. Shutter, D. Hockenbery, O. Kanagawa, M.J. Lenardo, and A.M. Peschon, and A. Strasser. 1997. Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1−/− mice. Cell. 89:1011–1019.
10. Jiang, D., M.J. Lenardo, and J.C. Zuniga-Pflucker. 1996. p53 prevents maturation to the CD4+ CD8+ stage of thymocyte differentiation in the absence of T cell receptor rearrangement. J. Exp. Med. 183:1923–1928.
11. Guidos, C.J., C.J. Williams, L. Grumbach, G. Knowles, M.T. Huang, and J.S. Danska. 1996. V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev. 10:2038–2054.
12. Jiang, D., M.J. Lenardo, and J.C. Zuniga-Pflucker. 1996. p53 prevents maturation to the CD4+ CD8+ stage of thymocyte differentiation in the absence of T cell receptor rearrangement. J. Exp. Med. 183:1923–1928.
13. Nakanishi, E., A.M. Carmena, and W.C. Earnshaw. 2001. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol. 11:49–54.
14. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88:323–331.
15. Schwartz, D., and V. Rotter. 1998. p53-dependent cell cycle control: response to genotoxic stress. Semin. Cancer Biol. 8:325–336.
16. Lanni, J.S., and T. Jacks. 1998. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol. Cell. Biol. 18:1055–1064.
17. Khan, S., and M.H. Wahl. 1996. p53 and pRB prevent replication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res. 58:396–401.
18. Stewart, Z.A., D. Mays, and J.A. Pietenpol. 1999. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res. 59:3831–3837.
19. Cross, S.M., C.A. Sanchez, C.A. Morgan, M.K. Schimke, S. Ramel, R.L. Idzerda, W.H. Raskind, and B.J. Reed. 1995. A p53-dependent mouse spindle checkpoint. Science. 267:1353–1356.
20. Minn, A.J., L.H. Boise, and C.B. Thompson. 1996. Expression of Bcl-xl and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev. 10:2621–2631.
21. Ambrosini, G., C. Adida, and D.C. Altieri. 1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3:917–921.
22. Marusawa, H., S. Matsuizawa, K. Welsh, H. Zou, R. Armstrong, I. Tammm, and J.C. Reed. 2003. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 22: 2729–2740.
23. Li, F., G. Ambrosini, E.Y. Chu, J. Plescia, S. Tognin, P.C. Marchisio, and D.C. Altieri. 1998. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584.
24. Kobayashi, K., M. Hatano, M. Otaki, T. Ogasawara, and T. Tokuhisa. 1999. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc. Natl. Acad. Sci. USA. 96:1457–1462.
25. Li, F., E.J. Ackermann, C.F. Bennett, A.L. Rothermel, J. Plescia, S. Tognin, A. Villa, P.C. Marchisio, and D.C. Altieri. 1999. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. 1:461–466.
26. Uren, A.G., L. Wong, M. Pakusch, K.J. Fowler, F.J. Burrows, D.L. Vaux, and K.H. Choo. 2000. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr. Biol. 10: 1319–1328.
27. Adams, R.R., M. Carmena, and W.C. Earnshaw. 2001. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol. 11:49–54.
28. Fraser, A.G., C. James, G.I. Evan, and M.O. Hengartner. 1999. Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis. Curr. Biol. 9:292–301.
29. Uren, A.G., T. Beilharz, M.J. O’Connell, S.J. Bugg, R. van Driel, D.L. Vaux, and T. Lithgow. 1999. Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division. Proc. Natl. Acad. Sci. USA. 96:10170–10175.
30. Speliotes, E.K., A. Uren, D. Vaux, and H.R. Horvitz. 2000. The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. Mol. Cell. 6:211–223.
31. Gianani, R., E. Jarboe, D. Orlicky, M. Frost, J. Bobak, R. Lehrer, and K.R. Shroyer. 2001. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum. Pathol. 32:119–125.
32. Conway, E.M., S. Pollefeyt, M. Steiner-Mosonyi, W. Luo, A. Devriese, F. Lupu, F. Bono, N. Leducq, F. Dol, P. Schaeffer, et al. 2002. Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology. 123:619–631.
33. Buchholz, F., P.O. Angrand, and A.F. Stewart. 1996. A simple assay to determine the functionality of Cre or FLP recombination targets in genomic manipulation constructs. Nucl. Acids Res. 24:3118–3119.
34. Okada, H., W.K. Suh, J. Jin, M. Woo, C. Du, A. Elia, G.S. Duncan, A. Wakeham, A. Itie, S.W. Lowe, et al. 2002. Generation and characterization of Smac/DIABLO-deficient mice. Mol. Cell. Biol. 22:3509–3517.
35. Ruland, J., G.S. Duncan, A. Elia, I. del Barco Barrantes, L. Nguyen, S. Flyte, D.G. Millar, D. Bouchard, A. Wakeham, P.S. Ohashi, et al. 2001. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell. 104:33–42.
36. Michie, A.M., S. Trop, D.L. Wiest, and J.C. Zuniga-
Pflucker. 1999. Extracellular signal–regulated kinase (ERK) activation by the pre–T cell receptor in developing thymocytes in vivo. *J. Exp. Med.* 190:1647–1656.

39. Hirao, A., Y.Y. Kong, S. Matsuoka, A. Wakeham, J. Ruland, H. Yoshida, D. Liu, S.J. Elledge, and T.W. Mak. 2000. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. *Science.* 287:1824–1827.

40. Rodriguez, C.I., F. Buchholz, J. Galloway, R. Sequerra, J. Kasper, R. Ayala, A.F. Stewart, and S.M. Dymecki. 2000. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. *Nat. Genet.* 25:139–140.

41. Orban, P.C., D. Chui, and J.D. Marth. 1992. Tissue- and site-specific DNA recombination in transgenic mice. *Proc. Natl. Acad. Sci. USA.* 89:6861–6865.

42. Shimizu, C., H. Kawamoto, M. Yamashita, M. Kimura, E. Kondou, Y. Kaneko, S. Okada, T. Tokuhisa, M. Yokoyama, M. Taniguchi, et al. 2001. Progression of T cell lineage restriction in the earliest subpopulation of murine adult thymus visualized by the expression of lck proximal promoter activity. *Int. Immunol.* 13:105–117.

43. Mombaerts, P., J. Iacomini, R.S. Johnson, K. Herrup, S. Tonegawa, and V.E. Papaioannou. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. *Cell.* 68:869–877.

44. Shinikai, Y., G. Rathbun, K.P. Lam, E.M. Oltz, V. Stewart, M. Mendelsohn, J. Charron, M. Datta, F. Young, A.M. Stall, et al. 1992. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(Dj) rearrangement. *Cell.* 68:855–867.

45. Mombaerts, P., A.R. Clarke, M.A. Rudnicki, J. Iacomini, S. Itohara, J.J. Lafaille, L. Wang, Y. Ichikawa, R. Jaenisch, M.L. Hooper, et al. 1992. Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. *Nature.* 360:225–231.

46. Molina, T.J., K. Kishihara, D.P. Siderovski, W. van Ewijk, A. Narendran, E. Timms, A. Wakeham, C.J. Paige, K.U. Hartmann, A. Veillette, et al. 1992. Profound block in thymocyte development in mice lacking p56lck. *Nature.* 357:161–164.

47. Levelt, C.N., P. Mombaerts, A. Iglesias, S. Tonegawa, and K. Eichmann. 1993. Restoration of early thymocyte differentiation in T-cell receptor beta-chain-deficient mutant mice by transmembrane signaling through CD3 epsilon. *Proc. Natl. Acad. Sci. USA.* 90:11401–11405.

48. Shinikai, Y., and F.W. Alt. 1994. CD3 epsilon-mediated signals rescue the development of CD4+CD8+ thymocytes in RAG-2−/− mice in the absence of TCR beta chain expression. *Int. Immunol.* 6:995–1001.

49. Giudine, A., M.J. Kallio, N.R. Wall, G.J. Gorbsky, S. Toggin, P.C. Marchisio, M. Symons, and D.C. Altieri. 2002. Regulation of microtubule stability and mitotic progression by survivin. *Cancer Res.* 62:2462–2467.

50. von Boehmer, H., and H.J. Fehling. 1997. Structure and function of the pre–T cell receptor. *Annu. Rev. Immunol.* 15: 433–452.

51. Silke, J., and D.L. Vaux. 2001. Two kinds of BIR-containing protein–inhibitors of apoptosis, or required for mitosis. *J. Cell Sci.* 114:1821–1827.

52. Altieri, D.C. 2003. Survivin, versatile modulation of cell division and apoptosis in cancer. *Oncogene.* 22:8581–8589.

53. Lens, S.M., R.M. Wolthuis, R. Klompmaker, J. Kauw, R. Agami, T. Brummelkamp, G. Kops, and R.H. Medema. 2003. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. *EMBO J.* 22:2934–2947.

54. Carvalho, A., M. Carmena, C. Sambade, W.C. Earnshaw, and S.P. Wheatley. 2003. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. *J. Cell Sci.* 116:2987–2998.

55. Fukasawa, K., T. Choi, R. Kuriyama, S. Rulong, and G.F. Vande Woude. 1996. Abnormal centrosome amplification in the absence of p53. *Science.* 271:1744–1747.

56. Tishler, R.B., D.M. Lamppu, S. Park, and B.D. Price. 1995. Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. *Cancer Res.* 55:6021–6025.

57. Tarapore, P., and K. Fukasawa. 2002. Loss of p53 and centrosome hyperamplification. *Oncogene.* 21:6234–6240.

58. Chen, S.S., P.C. Chang, Y.W. Cheng, F.M. Tang, and Y.S. Lin. 2002. Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. *EMBO J.* 21:4491–4499.

59. Anderson, S.J., K.M. Abraham, T. Nakayama, A. Singer, and R.M. Perlmutter. 1992. Inhibition of T-cell receptor beta-chain gene rearrangement by overexpression of the non-receptor protein tyrosine kinase p56lck. *EMBO J.* 11:4877–4886.